Advertisement

Breast Cancer Research and Treatment

, Volume 6, Issue 3, pp 221–227 | Cite as

Assessment of malignancy potential in so-called interval mammary carcinomas

  • Anette von Rosen
  • Kerstin Erhardt
  • Lars Hellström
  • Anders Somell
  • Gert Auer
Report

Summary

Forty-two so-called interval cancers of the breast were studied. The mammograms were reviewed and the tumors were classified as 14 ‘unrecognized’, 9 ‘observer error’, 1 ‘technical error’ and 18 ‘true’ interval cancers. By using a scoring system based upon histologic differentiation, axillary nodal status, estrogen receptor level, and nuclear DNA content, eight ductal carcinomas with high malignancy potential were identified. All of these tumors belonged to the group ‘true’ interval cancer. The data indicate that the mammographic subgroup ‘true’ interval cancer identifies the highly malignant tumors. However, even this strictly selected subgroup is heterogeneous since it also includes some tumors with low malignancy potential.

Key words

interval cancer breast carcinoma malignancy assessment DNA mammography screening 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DeGroote R, Rush BF Jr, Milazzo J, Warden MJ, Rocko JM: Interval breast cancer: a more aggressive subset of breast neoplasias. Surgery 94:543–547, 1983PubMedGoogle Scholar
  2. 2.
    Buchanan JB, Spratt JS, Heuser LS: Tumor growth, doubling times, and the inability of the radiologist to diagnose certain cancers. Radiol Clin North Am 21:115–126, 1983PubMedGoogle Scholar
  3. 3.
    Heuser LS, Spratt JS, Kuhns JG, Chang A F-C, Polk HC Jr, Buchanan JB: The association of pathologic and mammographic characteristics of primary human breast cancers with ‘slow’ and ‘fast’ growth rates and with axillary lymph node metastases. Cancer 53:96–98, 1984PubMedGoogle Scholar
  4. 4.
    Atkin NB: Modal deoxyribonucleic acid value and survival in carcinoma of the breast. Br Med J 1:271–272, 1972PubMedGoogle Scholar
  5. 5.
    Auer GU, Caspersson TO, Wallgren AS: DNA content and survival in mammary carcinoma. Anal Quant Cytol 2:161–165, 1980PubMedGoogle Scholar
  6. 6.
    Erhardt K, Auer G, Björkholm E, Forsslund G, Moberger B, Silfverswärd C, Wicksell G, Zetterberg A: Prognostic significance of nuclear DNA content in serous ovarian tumors. Cancer Res 44:2198–2202, 1984PubMedGoogle Scholar
  7. 7.
    Auer G, Eriksson E, Azavedo E, Caspersson T, Wallgren A: Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res 44:394–396, 1984PubMedGoogle Scholar
  8. 8.
    Erhardt K, Auer G, Fallenius A, Folin A, Forsslund G, Silfverswärd C, Zetterberg A: Mammary carcinoma: the prognostic significance of nuclear DNA analysis in histological sections. Am J Clin Oncol (in press)Google Scholar
  9. 9.
    Auer G, Ono J, Caspersson TO: Cytochemical identification of quiescent and growth-activated tumor cells. Anal Quant Cytol 5:5–8, 1983PubMedGoogle Scholar
  10. 10.
    World Health Organization: Histological Typing of Breast Tumors. International Histological Classification of Tumors No 2, 1968Google Scholar
  11. 11.
    Gustafsson J-A, Gustafsson SA, Nordenskjöld B, Okret S, Silfverswärd C, Wrange Ö: Estradiol receptor analysis in human breast cancer tissue by isoelectric focusing in polyacrylamide gel. Cancer Res 38:4225–4228, 1978PubMedGoogle Scholar
  12. 12.
    Adams LR: A photographic cytophotometric method which avoids distributional error. Acta Cytol 12:3–8, 1968PubMedGoogle Scholar
  13. 13.
    Holland R, Hendriks JHCL, Mravunac M: Mammographically occult breast cancer. Cancer 52:1810–1819, 1983PubMedGoogle Scholar
  14. 14.
    Martin JE, Moskowitz M, Milbrath JR: Breast cancer missed by mammography. Am J Roentgenology 132:737–739, 1979Google Scholar
  15. 15.
    Holland R, Mravunac M, Hendriks JHCL, Bekker BV: So-called interval cancers of the breast. Cancer 49:2527–2533, 1982PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1985

Authors and Affiliations

  • Anette von Rosen
    • 1
  • Kerstin Erhardt
    • 3
  • Lars Hellström
    • 2
  • Anders Somell
    • 1
  • Gert Auer
    • 3
  1. 1.Department of SurgeryKarolinska Institute at SödersjukhusetStockholmSweden
  2. 2.Department of RadiologyKarolinska Institute at SödersjukhusetStockholmSweden
  3. 3.Department of Tumor PathologyKarolinska Institute and HospitalStockholmSweden

Personalised recommendations